Pancreatic cancer risk (GLP-1 myth check)

What is Pancreatic cancer risk (GLP-1 myth check)?

An early worry from rodent studies showing acinar-cell hyperplasia.

Large human cohorts and the SELECT trial (Lincoff 2023, PMID 37952131) have NOT shown a pancreatic-cancer signal across years of follow-up, and the 2024 FDA Drug Safety Communication confirmed no causal association is established. ⚠ The boxed warning covers thyroid C-cell tumors and acute pancreatitis — not this. It is worth knowing which warnings are real when someone is frightening you toward or away from a purchase.

SELECT trial deep-dive (long-term safety) →

GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.

Where Pancreatic cancer risk (GLP-1 myth check) comes up on this site

Other terms under Side effects

• Cholelithiasis
• Ileus
• Telogen effluvium
• Ozempic face
• Medullary thyroid carcinoma (MTC)
• Lean mass loss
• GLP-1-induced gastroparesis
• Lipohypertrophy

Where the evidence lives

• SELECT trial deep-dive (long-term safety)
• The full GLP-1 glossary (149 terms, 8 categories)
• Research articles — written from primary sources
• Tools and calculators
• Compare GLP-1 telehealth providers